Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol in Pediatric Participants With Moderate to Severe Chronic Plaque Psoriasis
NCT04123795Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2020
- Primary completion
- Apr 2026
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 3
01
Overview
A Phase 3 trial of certolizumab pegol in plaque psoriasis, sponsored by UCB. Started Jan 2020; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04123795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123795.